首页> 外文OA文献 >Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study

【2h】

Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study

机译：在复发性多发性硬化中从皮下注射干扰素β-1a的原始制剂转变为新制剂后的患者满意度：一项随机，两臂，开放标签的IIIb期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Camu, William; Hadjout, Karim; Latour, Sabine; Pöhlau, Dieter; Masri, Said;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种 {"code":"en","name":"English","id":9}
中图分类

相似文献

外文文献
中文文献

1. Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study [J] . William Camu, Karim Hadjout, Sabine Latour, Patient Preference and Adherence . 2010,第2期

机译：在复发性多发性硬化症中从皮下干扰素β-1a的原始制剂转换为新制剂后的患者满意度：一项随机，两臂，开放标签的IIIb期研究
2. An Open-Label, Two-Arm, Randomised Study to Characterise Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning to Peginterferon Beta-1a (ALLOW): Interim Analysis Results [J] . Naismith R. T., Hendin B., Wray S., Multiple sclerosis: clinical and laboratory research . 2015,第6期

机译：一项开放标签，两臂随机研究，以表征复发性多发性硬化症患者转为聚乙二醇干扰素β-1a（ALLOW）的流感样症状：中期分析结果
3. Treatment de-escalation after mitoxantrone therapy: Results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis [J] . RieckmannP., HeidenreichF., SailerM., Therapeutic advances in neurological disorders. . 2012,第1期

机译：米托蒽醌治疗后的治疗恶化：一项关于复发性多发性硬化症患者皮下干扰素β-1a的IV期，多中心，开放标签，随机研究的结果
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized two-arm open-label Phase IIIb study [O] . William Camu, Karim Hadjout, Sabine Latour, 2010

机译：在复发性多发性硬化中从皮下注射干扰素β-1a的原始制剂转变为新制剂后的患者满意度：一项随机两臂开放标签的IIIb期研究
6. PND2 SAFETY AND IMMUNOGENICITY OF REBIF® NEW FORMULATION (RNF) A NEW SUBCUTANEOUS FORMULATION OF INTERFERON BETA-1A 44 MCG THREE TIMES WEEKLY: 1-YEAR RESULTS OF A PHASE IIIB STUDY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS [O] . Simsarian J, AL-Sabbagh A, Bennett R, 2007

机译：PND2REBIF®新配方（RNF）的安全性和免疫原性干扰素BETA-1A的新皮下配方44 mcg，每周三次：导致多发性硬化的患者进行IIIB期研究的一年结果

Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study

著录项

引文网络

相似文献

相关主题

期刊订阅